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Background: The ActualHCA™ system continuously monitors the activity, temperature and 
behavior of group-housed rats without invasive surgery.  The system was validated to detect 
the contrasting effects of sedative and stimulant test agents (chlorpromazine, clonidine and 
amphetamine), and compared with the modified Irwin test (mIT) with rectal temperature 
measurements.   
Methods: Six male Han Wistar rats per group were used to assess each test agent and 
vehicle controls in separate ActualHCA™ recordings and mIT.  The mIT was undertaken at 
15, 30 mins, 1, 2, 4 and 24h post-dose.  ActualHCA™ recorded continuously for 24h post-
dose under 3 experimental conditions: dosed during light phase, dark phase, and light phase 
with a scheduled cage change at the time of peak effects determined by mIT.   
Results: ActualHCA™ detected an increase stimulated activity from the cage change at 1-
2h post-dose which was obliterated by chlorpromazine and clonidine.  Amphetamine 
increased activity up to 4h post-dose in all conditions. Temperature from ActualHCA™ was 
affected by all test agents in all conditions.  The mIT showed effects on all 3 test agents up 
to 4h post-dose, with maximal effects at 1-2h post-dose.  The maximal effects on 
temperature from ActualHCA™ differed from mIT.  Delayed effects on activity were detected 
by ActualHCA™, but not on mIT. 
Conclusions: Continuous monitoring has the advantage of capturing effects over time that 
may be missed with manual tests using pre-determined time points.  Thisautomated 
behavioural system does not replace the need for conventional methods but could be 
implemented simultaneously to improve our understanding of behavioural pharmacology.  
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AUC  Area under the curve 
CNS  Central nervous system 
mIT  Modified Irwin test 
RFID  Radiofrequency identification 







Neurobehavioural assessments of drugs in rodents provide insights into 
pharmacological effects on the central nervous system (CNS) and are often 
conducted using manual measurements at pre-selected time points.  Automated 
methods of monitoring locomotor activity and behavior in laboratory rats have been 
emerging that can continuously assess the responses to test agents (Alexandrov et 
al., 2015; Dunne et al., 2007; Van de Weerd et al., 2001).  Automated systems have 
advantages over conventional manual observations that are often susceptible to 
observer bias, are of shorter duration and performed during the light phase only 
(Alexandrov et al., 2015; Dunne et al., 2007; Van de Weerd et al., 2001).  However, 
both these and more conventional locomotor activity systems require the use of 
single-housing (Redfern et al., 2017).  In contrast, modern laboratory practices have 
moved away from single-housing rats as it affects their behavior and welfare 
(Balcombe, 2006).   Moreover, automated methods such as continuous temperature 
monitoring requires invasive surgical implantation of radiotelemetry transmitters 
(Ansah et al., 1996; Bishop et al., 2001; Deveney et al., 1998; Harkin et al., 2002; 
Ossenkopp et al., 1994).  A recent approach that mitigates these concerns is the 
ActualHCA™ system (Actual Analytics, UK), which was developed as part of the 
“Rodent Big Brother project” funded by the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs), UK, to continuously 
monitor the activity and temperature of individual rats simultaneously when group-
housed in their home cage environment on a cage rack, without the need for 
invasive surgery (Redfern et al., 2017).   
 
The present study was conducted to validate the ActualHCA™ system by assessing 
its ability to detect changes in activity, temperature and behaviours in response to 
stimulant and sedative test agents, and to compare the results to the conventional 
manual approach: the modified Irwin test.  The Irwin test is a comprehensive, 
systematic qualitative observational assessment that was introduced to evaluate the 
neurobehavioural effects of drugs on mice (Irwin, 1968).  It has since been modified 
for use in rats and is currently used in safety pharmacology studies recommended by 
the International Conference on Harmonisation (ICH) S7A guideline for assessing 
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the effects of new chemical entities, to help protect clinical trials participants and 
patients from potential adverse effects ("International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use (ICH)," ; Redfern & 
Wakefield, 2006).  It is also used as a general observational test on rodents for 
assessing the neurobehavioural effects in disease models (Blokland et al., 1995; 
Hunter et al., 2000; Roux et al., 2004).   
 
Pharmacological validation of the system was conducted using well-characterised 
sedatives (chlorpromazine and clonidine), and a stimulant (amphetamine).  
Chlorpromazine was originally introduced as a neuroleptic agent in humans, and 
causes reduced activity, ataxia and lowered body temperature in rats (Mattsson et 
al., 1996; Moscardo et al., 2007).  Clonidine is a centrally-acting α2-adrenoreceptor 
agonist, which results in reduced activity and lowered body temperature in rodents 
(Drew et al., 1979; Drew et al., 1977; Ewart et al., 2013; Moscardo et al., 2007; Van 
der Laan & De Groot, 1988).  Amphetamine is a CNS stimulant first synthesised in 
1927 for the treatment of narcolepsy and mild depression (Heal et al., 2013).  Since 
then it has been useful for the treatment of attention deficit hyperactivity disorder 
(Heal et al., 2013).  Amphetamine works predominantly by increasing and sustaining 
the level of extracellular dopamine (Calipari & Ferris, 2013), and causes increase in 
locomotion, rearing and temperature in rats (Fog, 1970; Mattsson et al., 1996; 
Moscardo et al., 2007).   
 
The objective of this study was to explore how the capability of this new technology 
compares to that of the conventional modified Irwin test as a means in detecting 
functional effects of test agents with known pharmacological effects on the CNS 
(Table 1).  We also propose how the ActualHCA™ system could be integrated into 
the modified Irwin test to augment it.    
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2. Materials and methods 
 
2.1. Drugs 
Chlorpromazine hydrochloride was purchased from Sigma Aldrich, UK and was 
formulated with sterile water.  The formulated chlorpromazine was stored in the dark 
at 4oC.  Clonidine hydrochloride was purchased from Sigma Aldrich, UK and was 
formulated with sterile water.  The formulated clonidine was stored in the dark at 
room temperature.  D-Amphetamine sulfate salt was purchased from Tocris, UK and 
was formulated with sterile water.  The formulated amphetamine was stored in the 
dark at room temperature. 
 
2.2. Ethical statement 
The sample size of n=6 per treatment group was selected to have sufficient power to 
detect the effects reported  on the modified Irwin test (Ewart et al., 2013).  The Irwin 
test is designed to identify rare event symptoms as such we infrequently observe 
these within the control data and therefore seeing multiple symptoms within the 
treatment is a significant effect.  This design also gives a good sensitivity on 
subcutaneous temperature measured using ActualHCA™, which was achievable 
with n=6 because of the low variability of the data.  Two tailed Student’s T-test for 
temperature gives a power = 0.9 to detect a 1oC change with a variability of 0.48oC 
(Lenth, 2009).  The activity measure using ActualHCA™ has lower sensitivity when 
time points are considered in isolation due to high variation, this means the screen 
can detect median to large-sized activity effects that are sustained over multiple time 
points.  A total of 72 rats were used for the work described in this paper.  All 
procedures were conducted in accordance with the United Kingdom Animal 
(Scientific Procedures) Act 1986 and associated guidelines, approved by institutional 
ethical review committees (Alderley Park Animal Welfare and Ethical Review Board; 
Babraham Institute Animal Welfare and Ethical Review Board) and conducted under 
the authority of the Project Licences (40/3368 and 70/8307, respectively).  All animal 
facilities have been approved by the United Kingdom Home Office Licensing 
Authority and meet all current regulations and standards of the United Kingdom.  
7 
 
This manuscript has been prepared to meet the ARRIVE reporting guidelines 
(Kilkenny et al., 2010). 
 
2.3. Animals 
Twelve male Han Wistar (Crl:W1 (Han)) rats were used for the assessment of each 
drug and assessment methodology: with 6 animals in the control and 6 in the 
treatment group.  Rats (weight range 200-275g; age range 7-13 weeks at the start of 
data acquisition) were purchased from Charles River Laboratories, Margate, UK with 
vendor-supplied health reports indicated that the rats were free of known viral, 
bacterial and parasitic pathogens.  All rats were allocated to cages in 3s by body 
weight to balance the distribution of body weights between cages after arrival.  Rats 
remained housed in their social group throughout the duration of the study.  All rats 
were habituated for 7 days to the semi-barrier facility with temperature and relative 
humidity of +19oC to 23oC and 40% to 70%, respectively, prior to the start of any 
procedures.  Welfare of each rat was assessed throughout by daily monitoring of 
appearance, behavior and cage environment.  All rats had free access to food 
(RM1E, IRR 0.25 pelleted diet, Special Diet Services, UK) and water from the site 
drinking water supply.  Standard cages (Tecniplast model number 2000P, Italy) 
measured approximately 61.2 x 43.5 cm of floor space, and individually-ventilated 
cages (Tecniplast model number 1500IU, Italy) measured approximately 59 × 38 cm 
of floor space.  Both types of cages had 1-1.5 cm layer of 4 mm3 bedding material 
consisted of aspen wooden chips (Eco-Pure™ Aspen Chips 4), soft nesting material, 
ENVIRO-dri sizzle nest and Aspen chew blocks (Datesand, UK).   
 
Naïve rats were used for the Irwin experiments prior to the start of dosing.  Rats 
tested with the ActualHCA™ system were implanted in-house with a temperature-
sensitive passive radiofrequency identification (RFID) transponder (BioTherm13, 
Biomark, USA) subcutaneously in the ventral abdominal midline at least 7 days prior 
to the start of dosing.  For the Irwin experiments, the holding and experimental room 
light cycle were in the darkness from 18:00h to 06:00h, and lit from 06:00h to 18:00h.  
For the ActualHCA™ experiments, the holding and experimental room light cycle in 
the facility were in darkness from 19:00h to 07:00h, and lit from 07:00h to 19:00h.  
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For the Irwin experiments, each cage contained a cardboard tunnel as environmental 
enrichment.  For the ActualHCA™ experiments, each cage contained a red 
translucent play tunnel in order for the camera to see through the tunnel, which 
appears clear under infrared light (Redfern et al., 2017).  For each experiment, six 
rats were used per treatment group and a vehicle counterpart (sterile water) was 
used as control per test agent.  A single oral gavage dose of 30 mg/kg 
chlorpromazine, or 0.3 mg/kg clonidine, or 10 mg/kg amphetamine, or their vehicle 
counterparts (10 mL/kg) was administered to the rats.  The dose levels for 
chlorpromazine, clonidine and amphetamine were selected based on information 
derived from the literature, which showed extensive sedative and stimulant effects in 
neurobehavioural assessments (Ewart et al., 2013; Strang, 2005). 
 
2.4. Modified Irwin tests 
On the day of the experiments, rats were weighed and administered the appropriate 
drug treatment, and observed at 15, 30 minutes, 1, 2, 4 and 24 hours post-dose in 
sequential order based on the order of dosing.  The observer was not blind to 
treatment regimes to prevent dosing errors.  Blinding was not practically possible 
within our animal facility because the treatment groups are currently used as a point 
of identification on the cage cards, and there was only one operator.  This operator, 
who undertakes Irwin assessments routinely, has no investment in the outcome of 
the experiment and did not analyse the data.  Furthermore, the effects of the drugs 
were pronounced and readily identifiable.  The Irwin parameters (Ewart et al., 2013; 
Irwin, 1968) were assessed systematically, starting with the home cage observation 
followed by the handling observation.  The incidence of rats exhibiting symptoms 
was recorded.  The observed symptoms for each rat were scored from 1 to 3 based 
on severity of the symptom, where ‘1’ indicates mild, ‘2’ indicates moderate and ‘3’ 
indicates pronounced (see Supplementary Table S1).  The observed symptoms for 
each treatment group at each observed time point were then presented as the dose 
group mean of the percentage of the maximal possible score (%MPS) [score/max 
score*100].  Rectal temperature was measured at 1, 4 and 24h post-dose for 
chlorpromazine and amphetamine; and at 1h post-dose for clonidine, using a 
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thermometer with a flexible temperature-sensitive probe (Physitemp thermalert 
model TH-8) inserted approximately 2 cm past the anal sphincter.  
 
2.5. ActualHCA™ monitoring: microchip implantation 
The transponders were purchased in pre-sterilised and pre-loaded single-use needle 
form.  All rats were anaesthetised with isoflurane (induced at 4.5%, maintained at 3-
4% with 2L oxygen) prior to the implantation.  The ventral abdominal region was 
shaved and swabbed using antiseptic pre-surgical scrub.  A small (<5mm) 
transverse incision was made through the skin using sterile scissors, to allow 
insertion of sterile blunt scissors to create a subcutaneous pocket using blunt 
dissection.  A pre-sterilised trocar needle (pre-loaded with the transponder) was 
used to introduce the transponder using the plunger, in a rostrocaudal orientation.  
The wound was then sealed using topical tissue adhesive (GLUture®, Abbott 
Laboratories, UK).  The rat remained under anaesthesia until the adhesive had dried.  
Rats were left to recover from 3-10 days post-implantation to ensure the transponder 
did not fall out before experimentation.  Of 36 rats implanted in this study, the RFID 
transponder extruded externally from the implantation site in 1 rat, and was replaced.  
There were no other welfare issues associated with the implantation. 
2.6. ActualHCA™ monitoring 
The system can record temperature and horizontal (ambulatory) activity via the 
implanted RFID transponder, and the behavior from the side-on high definition infra-
red video camera (Redfern et al., 2017).  For each test agent, 2 days’ baseline data 
were collected prior to agent administration and data collection continued for 24 
hours post-administration. An additional 3 days were allowed between treatments to 
ensure wash-out of the test agents (Table 2).  For each test agent, a concurrent 
randomised design was used with  6 animals treated with vehicle and 6 animals 
treated with test agent.  Through the continuous monitoring, all rats were assessed 
in 3 different experimental conditions: ‘light phase’ - dosed during the light phase (at 
approximately 09:00h); ‘ dark phase’ - dosed during the dark phase (at 
approximately 20:00h); ‘cage change’ - dosed during the light phase followed by a 
cage change at the maximal effect of the drug determined from the Irwin test 
(chlorpromazine: 2h post-dose; clonidine: 1h post-dose; amphetamine: 2h post-
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dose).  Two cages (each containing 3 rats) were randomly allocated per treatment 
group based on the pre-dose mean ambulatory activity per cage (expressed as the 
number of transitions for that cage) measured over 24 h period, in order to balance 
the baseline activity levels for the vehicle and the drug-treated groups as much as 
possible.  All rats were weighed on the day of dosing and dosed with the appropriate 
drug treatment.   
 
Raw data of movement and subcutaneous temperature for individual rats were 
recorded via the transponder.  Vertical activity was determined using the video 
footage and processed using ActualHCA™.  Vertical activity is defined as any 
movement above a vertical threshold, set at 8 cm above the cage floor at the far wall 
of the cage (Redfern et al., 2017).  Raw activity, temperature data and the video files 
were filtered to remove any artefactual noise (Redfern et al., 2017) and binned into 
30-minute bins using ActualHCA™ (version 2.2.4.).  Manual ‘Irwin-style’ behavioural 
assessment using the video footage recorded during the ‘light phase’ was performed 
post hoc at the same pre-determined time points as the conventional modified Irwin 
test that was conducted live in the laboratory in a separate group of animals.  The 
‘light phase’ was chosen for dosing regimen as this approach was most comparable 
to the conventional Irwin experiment.  Additional delayed time points for the manual 
‘Irwin-style’ behavioural assessments were also performed using the ActualHCA™ 
video, based on the activity profile detected by ActualHCA™.  All home cage 
observed elements of the modified Irwin test were manually assessed using the 
video (see Supplementary Table S1), and only effects with abnormal findings were 
reported.  The purpose was to confirm the delayed effects detected from the RFID 
transponder with behavioural assessment.  The additional time points for 
chlorpromazine were at 01:00h, 02:00h and 03:00h (16, 17 and 18 hours post-dose, 
respectively); clonidine at 21:00h and 23:30h (12 and 14.5 hours post-dose); and 
amphetamine at 17:00h, 21:00h and 23:00h (8, 12 and 14 hours post-dose, 
respectively).  The manual video assessment took place using the first 5 minutes of 
the 30-minute-binned video footage. 
 
2.7. Statistical analysis 
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The data analysis treated each animal as the experimental unit.  Effects in the Irwin 
test were considered significant if half or more of the rats in a given treatment group 
exhibited the symptom (e.g. ≥n=3 out of 6)(Ewart et al., 2013).  This is appropriate 
for these symptoms because they are rare symptoms in the control data.  In effect, 
the operator is comparing the treated group to the baseline historic data and the 
local controls are contributing to this data.  For example, a power greater than 0.854 
is obtained with a one sample test of proportions when the abnormality rate of 
interest is greater than 50% and the baseline abnormality rate is less than 7.5% 
(Lenth, 2009).  Body temperature was analysed using a two-tailed student’s t-test 
adjusted to control the false discovery rate to 5% for datasets for a variable and drug 
using the Benjamini and Hochberg methodology (Benjamini & Hochberg, 1995).  For 
filtered activity, temperature, and vertical activity data, statistically significant 
differences were identified by comparing drug-treated groups with their time-matched 
vehicle counterparts using a two-tailed student’s t-test.  The multiple testing problem 
was managed by adjusting the p values to control the false discovery rate to 5% in 
each dataset which comprised of all the tests for a variable and drug using the 
Benjamini and Hochberg methodology (Benjamini & Hochberg, 1995).  Area under 
the curve (AUC) was calculated for activity, temperature and vertical activity of all 
animals using the composite trapezoid rule for 0-24h post-dose.  The AUC for drug-
treated groups was then compared with their vehicle counterparts using a two-tailed 
student’s t-test.  P-values were adjusted to control the false discovery rate to 5% 
using the Benjamini and Hochberg methodology and those of less than 0.05 was 
considered significant (Benjamini & Hochberg, 1995).   
 
2.8. Data availability 







3.1. Modified Irwin test 
In our study, the effects of chlorpromazine, clonidine and amphetamine were 
consistent with their known pharmacology (Ewart et al., 2013; Fog, 1970; Holman et 
al., 1971; Mattsson et al., 1996; Moscardo et al., 2007).  The duration of effects for 
all 3 drugs were observed to be from 15 mins to 4 hours post-dose (Table 3).  For 
chlorpromazine, the majority of and most pronounced behavioural effects were 
observed at 2 hours post-dose, with 7 significant findings and spontaneous activity 
decreased reaching up to 100% severity score (Table 3), and the mean maximum 
decrease in body temperature of 1.3oC occurred at 1 hour post-dose (Table 4).  For 
clonidine, the majority of and most pronounced effects were observed at 1 hour post-
dose, with 6 significant findings and spontaneous activity decreased reaching up to 
83% severity score (Table 3), where the mean maximum decrease in body 
temperature of 2.1oC also occurred (Table 5).  For amphetamine, the majority of and 
most pronounced effects were observed at 2 hours post-dose, with 5 significant 
findings and touch response increased reaching up to 83% severity score (Table 3), 
and the mean maximum increase in body temperature of 1oC occurred at 4 hours 
post-dose (Table 6). 
 
3.2. Effects on activity detected by ActualHCA™  
 
3.2.1. Chlorpromazine 
The activity profile of chlorpromazine differed between the 3 experimental conditions.  
When dosed during the light phase, chlorpromazine caused a statistically significant 
reduction in ambulatory and vertical activities immediately post-dose compared to its 
time-matched vehicle group (P<0.05; Figure 1A and B).  However, a delayed 
reduction in ambulatory activity was more prominent at 01:00h and 02:00h overnight 
(16 and 17 hours post-dose, respectively)(Figure 1A and B).  The AUC0-24h overview 
measure highlighted statistically significant reduction in ambulatory activity 
(P=0.000047) and in time spent in vertical activity (P=0.00014) when chlorpromazine 
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was dosed during the light phase.  When dosed in the dark phase, chlorpromazine 
caused a statistically significant delayed reduction in ambulatory and vertical 
activities at 10:00h the following morning (14 hours post-dose)(Figure 1C and D).  
The AUC0-24h overview measure highlighted significant reduction in ambulatory 
activity (P=0.013) and in time spent in vertical activity (P=0.012) when 
chlorpromazine was dosed during the dark phase.  When dosed during the light 
phase with a scheduled cage change at 2 hours post-dose, chlorpromazine caused a 
statistically significant reduction in stimulated ambulatory activity from 2 to 2.5 hours 
post-dose and in vertical activity at 1 and 2 hours post-dose (Figure 1E and F).  The 
AUC0-24h overview measure highlighted a statistically significant reduction in 
ambulatory activity (P=0.00075) but no significant effects on time spent in vertical 
activity (P=0.60) when chlorpromazine was dosed in the light phase with a scheduled 
cage change.  In conclusion, the transient stimulation of activity caused by a cage 
change in the vehicle animals was prevented by chlorpromazine treatment, which is 
in agreement with the effects of chlorpromazine causing reduced activity (Moscardo 
et al., 2007). 
 
3.2.2. Clonidine 
The activity profile of clonidine also differed between the 3 experimental conditions.  
When dosed in the light phase, clonidine caused a statistically significant delayed 
increase in ambulatory activity at 06:00h and 07:00h the next day (21 and 22 hours 
post-dose) and delayed increase in vertical activity from 04:00h to 07:30h the next 
day (19 to 22.5 hours post-dose)(P<0.05; Figure 2A and B).  The AUC0-24h measure 
highlighted no significant reduction in ambulatory activity (P=0.97), but the reduction 
was statistically significant on time spent in vertical activity (P=0.003) when clonidine 
was dosed during the light phase.  This effect in the light phase was inconsistent with 
the pharmacology of clonidine from the literature as clonidine was shown to reduce 
activity in rats (Drew et al., 1979; Drew et al., 1977; Ewart et al., 2013).  When dosed 
in the dark phase, clonidine caused no changes in ambulatory activity up to 24 hours 
post-dose (Figure 2C).  However, clonidine caused a statistically significant reduction 
in time spent in vertical activity from 02:30h to 06:30h overnight (6.5 to 10.5 hours 
post-dose, respectively)(P<0.05; Figure 2D).  The AUC0-24h measure highlighted no 
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significant reduction in ambulatory activity (P=0.13) but the reduction was statistically 
significant on time spent in vertical activity (P=0.0017) when clonidine was dosed in 
the dark phase.  When dosed in the light phase with a scheduled cage change at 1 
hour post-dose, clonidine caused a significant reduction in stimulated ambulatory 
activity from 1 to 1.5 hours post-dose, a delayed significant reduction in activity at 
22:30h (13.5 hours post-dose) and a significant delayed increase in activity at 07:00h 
(22 hours post-dose) hours post-dose (P<0.05; Figure 2E). Clonidine also caused a 
significant reduction in stimulated time spent in vertical activity from immediately 
post-dose to 1.5 hours post-dose (P<0.05; Figure 2F).  The AUC0-24h measure 
highlighted significant reduction in ambulatory activity (P=0.040) and in time spent in 
vertical activity (P=0.0016) when clonidine was dosed during the light phase with a 
scheduled cage change.  In summary, the transient stimulation of activity caused by 
a cage change in the vehicle animals was obliterated by clonidine treatment, which 
was in agreement with the effects of clonidine causing reduced activity in rats (Drew 
et al., 1979; Drew et al., 1977; Ewart et al., 2013). 
 
3.2.3. Amphetamine 
The effects of amphetamine in all 3 experimental conditions were consistent with its 
pharmacology from the literature (Fog, 1970; Mattsson et al., 1996; Moscardo et al., 
2007).  When dosed in the light phase, amphetamine caused a significant increase 
in ambulatory and vertical activities from immediately post-dose to 6.5 hours post-
dose (P<0.05; Figure 3A and B).  The AUC0-24h measure highlighted a significant 
increase in ambulatory activity (P=0.012) and in time spent in vertical activity 
(P=0.0015) when amphetamine was dosed during the light phase.  When dosed in 
the dark phase at 20:00h, amphetamine caused a significant increase in ambulatory 
and vertical activities from 0.5 to 8 hours post-dose (P<0.05; Figure 3C and D).  The 
AUC0-24h measure highlighted a significant increase in ambulatory activity (P=0.0078) 
but effects were not significant on time spent in vertical activity (P=0.065) when 
amphetamine was dosed in the dark phase.  When dosed in the light phase with a 
scheduled cage change at 2 hours post-dose, amphetamine caused significantly 
increased stimulated ambulatory and vertical activities from 0.5 to 6.5 hours post-
dose (P<0.05; Figure 3E and F).  The AUC0-24h measure highlighted significant 
increase in ambulatory activity (P=0.00092) and in time spent in vertical activity 
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(P=0.00069) when amphetamine was dosed during the light phase with a scheduled 
cage change.   
 
3.3. Effects on subcutaneous temperature detected by ActualHCA™  
 
3.3.1. Chlorpromazine 
The effects of chlorpromazine on subcutaneous temperature were consistent in all 3 
experimental conditions and in concordance with its known pharmacology (Mattsson 
et al., 1996; Moscardo et al., 2007). The maximum decrease in temperature of 1.5oC 
when dosed during the light phase occurred 3.5 hours post-dose (Figure 4A), when 
dosed during the dark phase, a maximum decrease of 1.4oC  occurred at 3 hours 
post-dose (Figure 4B), and when dosed during the light phase with scheduled cage 
change, a maximum decrease of 1.7oC  occurred 2.5 hours post-dose (Figure 4C).  
The AUC0-24h measure highlighted statistically significant effects when dosed in the 
light phase (P=0.016), however, effects were not statistically significant when dosed 
in the dark phase (P=0.14) or dosed in the light phase with a scheduled cage change 
(P=0.16).   
 
3.3.2. Clonidine 
The effects of clonidine on subcutaneous temperature were consistent in all 3 
experimental conditions and in concordance with its known pharmacology (Drew et 
al., 1979; Drew et al., 1977; Ewart et al., 2013; Moscardo et al., 2007).  The 
maximum decrease in body temperature of 1.5oC when dosed during the light phase 
occurred at 2.5 hours post-dose (Figure 4D), when dosed during the dark phase, a 
maximum decrease of 2.7oC  occurred at 4.5 hours post-dose (Figure 4E), and when 
dosed during the light phase with scheduled cage change, a maximum decrease of 
2.9oC  occurred at 1.5 hours post-dose (Figure 4F).  The AUC0-24h measure was not 
statistically significant when dosed in the light phase (P=0.46), however, effects were 
statistically significant both when dosed in the dark phase (P=0.0043) and when 





The effects of amphetamine on subcutaneous temperature were consistent in all 3 
experimental conditions and in concordance with its known pharmacology (Fog, 
1970; Mattsson et al., 1996; Moscardo et al., 2007).  The maximum increase in 
temperature of 1.5oC when dosed during the light phase occurred at 2 hour post-
dose (Figure 4G), when dosed during the dark phase, a maximum increase of 1.8oC 
occurred at 2 hours post-dose (Figure 4H), and when dosed during the light phase 
with a scheduled cage change, a maximum increase of 1.9oC occurred at 1.5 hours 
post-dose (Figure 4I).  However, the AUC0-24h measure was not statistically 
significant when dosed in the light phase (P=0.99), dosed in the dark phase (P=0.48) 
nor when dosed in the light phase with a scheduled cage change (P=0.10). 
 
3.4. Manual behavioural assessment from ActualHCA™ video vs. conventional 
modified Irwin test 
To validate the manual behavioural assessment collected from ActualHCA™ videos, 
an independent experiment undertaking the conventional home cage observation 
component of the modified Irwin test data was performed on control and treated 
animals.  The effects of chlorpromazine and clonidine on decreased spontaneous 
activity were consistent between both methods.  The effects of amphetamine on 
increased spontaneous activity, rearing and sniffing were also consistent between 
both methods (Tables 3, 4 and 5).  An effect of chlorpromazine on abnormal gait was 
observed from the video footage, but not from the live test (Table 4).  An effect of 
chlorpromazine on piloerection was observed in the live test, but not from the video 
footage (Table 4).  Piloerection caused by amphetamine in the live test were 
observed on several time points, which were also more pronounced than what was 
seen with chlorpromazine.  However, significant piloerection from the video footage 
was only observed at one time point, and was seen as less pronounced (Table 6).  
Since piloerection as a phenotype does not affect all animals exposed to 
chlorpromazine then the difference between the two studies could arise from a 




3.5. Delayed behavioural findings from the ActualHCA™ monitoring 
Three additional time points of ‘Irwin-style’ post hoc assessment for each test agent 
were performed using the video footage captured with ActualHCA™ during the ‘light 
phase’ dosing protocol.  These time points were selected after evaluating the test 
agents on the 24h post-dose activity profile detected from the RFID transponder.  At 
these additional time points, chlorpromazine was observed to cause significantly 
decreased spontaneous activity at 16 and 17 hours post-dose, in the video (Table 7), 
where the automated ambulatory activity was significant decreased compared to 
vehicle (Figure 1).  Clonidine was observed to cause significantly increased 
spontaneous activity at 14.5 and 21 hours post-dose, in the video (Table 7), where 
the automated ambulatory activity showed decreasing trends at 12 and 14.5 hours 
post-dose, and significant increased activity at 21 hours post-dose (Figure 2). 
Amphetamine significantly decreased spontaneous activity at 12 and 14 hours post-
dose, in the video (Table 7), where the automated ambulatory activity was significant 







4.1. The added value of the ActualHCA™ system 
The ActualHCA™ system improves automated detection compared to other systems 
through the ability to monitor group housed animals without the need for specialised 
housing or invasive surgery.  The objective of this study was to validate the 
ActualHCA™ system pharmacologically with test agents and to compare the results 
with a manual qualitative observational assessment (modified Irwin test) that is 
widely used for assessing the neurobehavioural effects of new chemical entities.  
The pharmacological validation study showed that the ActualHCA™ system was 
able to detect effects on ambulatory and vertical activities, and subcutaneous 
temperature for the test agents chlorpromazine, clonidine and amphetamine.  The 
observed findings were consistent with the known pharmacology of these test agents 
in rats (Fog, 1970; Heal et al., 2013; Mattsson et al., 1996; Moscardo et al., 2007; 
Van der Laan & De Groot, 1988).  Their effects on activity and temperature, as 
detected using the modified Irwin test and ActualHCA™ were in agreement, despite 
using different cohorts of animals in independent experiments.  These results show 
that the automated monitoring of the ActualHCA™ system can be used as an 
alternative method for assessing locomotor activity and temperature effects of new 
chemical entities.  
 
Compared to an automated continuous monitoring method, a disadvantage of the 
conventional modified Irwin test is the use of pre-determined time points which can 
miss the maximum effect.  For example, the effect of chlorpromazine on 
subcutaneous temperature using ActualHCA™ was consistent in all 3 experimental 
conditions, with maximum effects observed within 2.5 to 3.5 hours post-dose.  
However, from the live modified Irwin test, where body temperature measurements 
were set at 1, 4 and 24 hours post-dose, the maximum effect on temperature was 
observed at 1 hour post-dose.  A further benefit of automated continuous monitoring 
is the ability to detect delayed effects.  Any functional effects that do not directly 
correlate with the pharmacokinetics of a test agent (e.g. delayed effects) can be 
missed when using manual pre-determined time points.  In 2 of the 3 drugs studied, 
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delayed effects were observed.  For example with chlorpromazine, an effect on 
ambulatory activity was observed at 16 and 17 hours post-dose, whereas, based on 
the neurobehavioural profile of chlorpromazine using conventional manual 
observations, the effects on behavior would have been expected to have subsided 
by 8 hours post-dose (Moscardo et al., 2007).  Any compensatory or rebound effects 
following the initial response to test agents may also be missed with pre-determined 
time points for manual observation based on the pharmacokinetic profile.  This was 
demonstrated with clonidine and amphetamine, where delayed reverse effects of 
their pharmacology were observed.  The rebound effect of clonidine has previously 
been demonstrated following 3 daily doses on locomotor activity (Van der Laan & De 
Groot, 1988).   
 
Most routine behavioural observations and measurements in rodents are conducted 
during the light phase for practical reasons. However, as rats are nocturnal, sedative 
effects may not be detected during the light phase.  A scheduled cage change was 
included within the experiment to introduce a novel environment which would 
transiently increase exploratory activity.  The rationale for doing this was that this 
might provide a brief window to detect sedative effects during the light phase.  This 
strategy was successful, as demonstrated with 2 sedative agents used in this study.  
The ActualHCA™ system can acquire data during the dark phase where animals are 
naturally active. however, dosing prior to a transient stimulation has benefits.  This is 
analogous to a conventional assessment of locomotor activity in a novel arena, 
except that rats are group-housed with their cagemates.  The data from the 
scheduled cage change will be comparable with other studies, which are frequently 
performed during the light phase.  Furthermore, drug metabolism has been shown to 
differ depending on the time of day (Gachon & Firsov, 2011; Radzialowski & 
Bousquet, 1968), therefore dosing during the dark phase can potentially alter the 
pharmacokinetic profile of the test agent.   
 
Another advantage of continuous measurements of body temperature is the 
reduction of stress leading to a more representative measure.  Body temperature 
measurements for the modified Irwin test require handling the animals and inserting 
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a rectal probe at each pre-determined time point.  This method limits the number of 
body temperature measurements performed each day.  The body temperature of 
animals also increases due to the stress of the handling procedure (Balcombe et al., 
2004; Clement et al., 1989; Dilsaver et al., 1992; Eikelboom, 1986; Moe & Bakken, 
1997).  Although, the ActualHCA™ measures subcutaneous temperature rather than 
core temperature, the rectal temperture used at the modified Irwin test is also not 
equivalent to core temperature (Dilsaver et al., 1992).  Mean rectal temperature in 
the rat ranges from 30-38oC with higher temperatures detected the further the probe 
pasts the anal sphincter (Lomax, 1966).  Mean core temperature from the rat ranges 
from 36.5 to 38oC, depending on the time of day (Gordon et al., 2002).  
Subcutaneous temperature measured using the ActualHCA™ in the rat ranges from 
35.1 to 37.2oC, with a mean subcutaneous temperature of 36.0oC ± 0.05 (mean ± 
95% confidence interval) during the light phase, and 36.2oC ± 0.07 (mean ± 95% 
confidence interval) during the dark phase (Redfern et al., 2017).  Rectal 
temperature can reach the range of core temperature when the probe reaches 
beyond 4 cm past the anal sphincter (Lomax, 1966).  However, the temperature 
probe for modified Irwin test was inserted 2 cm past the anal sphincter, therefore the 
temperature measured would be lower than core temperature.  To measure core 
temperature continuously would require invasive surgical implantation of an 
intraperitoneal telemetry device (Gordon et al., 2002).  
 
Maximum benefit from the system can be obtained by combining the continuous 
home cage monitoring with the modified Irwin test.  The video footage enables post 
hoc assessments of the observational ‘non-interactive’ elements of the modified Irwin 
test.  The elements that require handling e.g. traction response, touch response, or 
those that require close observations e.g. pupil size cannot be assessed.  The post 
hoc assessment can be implemented wherever the user feels is most appropriate, 
for example at the compound’s Tmax (see Supplementary Figure S1).  The use of an 
automated behavioural system does not directly replace the need for conventional 
approaches, but can work in synergy to provide non-subjective, additional 
measurements that are not achievable through manual observations, including 
measurements and observations during the dark phase in undisturbed animals.  
Therefore, the ActualHCA™ system could be combined both with post hoc Irwin 
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home cage observations on demand and a planned conventional modified Irwin test 
at the Tmax.  From our observations on the benefits of a cage change to present a 
transient novel environment, a conventional modified Irwin test could be combined 
with this event in the light phase as our data clearly demonstrated that this would 
reveal the effects of sedative agents without obscuring the effect of a stimulant. 
 
Obviously the technology has numerous other potential applications besides 
integration into the modified Irwin test.  Various authors have encouraged the 
inclusion of behavioural endpoints in rodent repeat-dose toxicology studies over the 
last three decades (Evans, 1989; Luft & Bode, 2002; Redfern, 2015; Redfern et al., 
2013; Zbinden, 1984).  Deployment of ActualHCA™ in early repeat-dose toxicology 
studies in rats would provide valuable additional data on adverse effects of new 
molecular entities on activity, behavior and temperature, as we have demonstrated 
with these three reference drugs after a single dose. Such effects can increase, 
diminish or remain the same on repeated dosing (Redfern et al., 2013).  Another 
obvious application in the field of CNS safety assessment is in the detection of drug 
dependence.  Typically, these studies involve repeat dosing of rodents daily for (say) 
3 weeks, followed by cessation of dosing. The animals are then monitored using a 
combination of manual and automated approaches to look for signs of physiological 
and behavioural withdrawal phenomena (Anon, 2006, 2017; Balster, 1991; Porsolt et 
al., 2002; Swedberg, 2013).  Depending on the pharmacological class, these 
withdrawal syndromes commonly involve changes in horizontal and vertical activity, 
and temperature (Ohmura et al., 2011).  Furthermore, ActualHCA™ has potential 
applications across the entire spectrum of behavioural neuroscience and drug 
discovery: activity/behavioural phenotyping of different rat strains and transgenic 
animals (e.g.(McDermott & Kelly, 2008)); circadian biology (e.g., (De La Iglesia et al., 
2008); fever studies (e.g. (de Melo Soares et al., 2017)); neurological and other 
disease models (e.g. (Percie du Sert et al., 2017).  In the field of animal husbandry 
and welfare it would provide the opportunity for stringent, objective, undisturbed 
evaluation of preference for different bedding, caging and environmental enrichment 
etc. (Balcombe, 2006). It would also enable early identification of individual animals 
at risk in repeat-dose toxicity studies, disease models, etc., as they would be 
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expected to exhibit hypoactivity and hypothermia (Gordon, 1991; Percie du Sert et 
al., 2017).  
 
4.2. Considering clinical translation 
The purpose of an Irwin test prior to clinical trials (Phase I) is to protect healthy 
volunteers and patients from harmful effects of candidate drugs on the nervous 
system.  A recent analysis of the predictive value of the Irwin test was undertaken on 
141 candidate drugs that had proceeded to be tested in Phase I single ascending 
dose studies (Mead et al., 2016).  This translational analysis was limited to common 
adverse effects, and found that these were poorly predicted from the Irwin 
parameters, included amongst these were somnolence and fatigue.  A possible 
impediment to translation is the observation that there are inter-laboratory 
differences in outcomes from the Irwin test (Ewart et al., 2013).  These can arise 
from strain, age or batch differences between rats, inter-observer differences in 
interpretation/assessment/scoring of behaviours, or from operational differences 
affecting baseline activity of the rats (Moscardo et al., 2007).  Operational differences 
include the level of prior handling of the animals, lighting levels and background 
noise, the time allowed from moving animal racks to the area where the Irwin test will 
be conducted before commencing the procedures, the time from removal of a cage 
from the rack to commencement of the observations – and even the time from 
opening the cage lid to the observations (Ewart et al., 2013).  Automated detection of 
effects on activity (which are plausibly associated with somnolence or fatigue), and 
extension of manual Irwin observations beyond the conventional working day and 
into the animal’s active dark phase, could contribute to improving the translation 
between preclinical assessment of CNS effects in rodents and CNS safety outcomes 




This study has demonstrated that ActualHCA™ can detect pharmacological changes 
in activity, temperature and behavior from two sedatives and a stimulant.  Compared 
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with the modified Irwin test, ActualHCA™ can consistently detect changes as seen in 
the modified Irwin test, albeit those limited to ‘non-interactive’ elements of this test.  
Furthermore, ActualHCA™ can provide advantages from the longer duration of 
continuous automated measurements which can highlight additional behavioural 
effects of the test agents to those achievable using conventional approaches.  Using 
automated home cage behavioural monitoring of group-housed rats can help 
improve our understanding of the pharmacological effects of test agents on the CNS. 
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Test agent Animal 
cohort 
ActualHCA™ system Animal 
cohort 
Modified Irwin test 
Chlorpromazine 1 Dosed and assessed 
on 3 different 
experimental 
conditions: ‘Light 
phase’, ‘dark phase’ 
& ‘cage change’ 
4 Dosed and assessed 
conventionally 
Clonidine 2 Dosed and assessed 
on 3 different 
experimental 
conditions: ‘Light 
phase’, ‘dark phase’ 
& ‘cage change’ 
5 Dosed and assessed 
conventionally 
Amphetamine 3 Dosed and assessed 
on 3 different 
experimental 
conditions: ‘Light 
phase’, ‘dark phase’ 
& ‘cage change’ 
6 Dosed and assessed 
conventionally 
 
Table 1. A study design table, illustrating the different experimental objectives, 
tested by ActualHCA™ and the conventional modified Irwin test 
A table illustrating the study design and the cohort of animals used for each 
experiment and each test agent.  The objective was to compare the capability of 
ActualHCA™ vs. the conventional modified Irwin test, in detecting functional effects 






 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Week -3   Arrival Habituate Habituate Habituate Habituate 
Week -2 Habituate Habituate Transponder 
implantation:  
Recovery Recovery Recovery Recovery 
Week -1* Recovery Recovery Recovery Recovery Recovery Recovery Recovery 









Day 2  Washout  Washout Washout 












Day 2  Washout  Washout Washout 











Day 2  Washout  Washout Washout 
Table 2.  A study timing table, illustrating the timelines of the different 
experimental conditions tested using ActualHCA™ per test agent.A table 
illustrating the timelines from animals arrival to radiofrequency identification (RFID) 
transponder implantation, and dosing of the test agent for each experimental 
condition.  *Additional week for recovery was only required when the RFID 




Group Symptoms observed 15 min 30 min 1h 2h 4h 24h 
Vehicle for 
chlorpromazine 




Spontaneous activity decreased 17% (3) 56% (6) 78% (6) 100% (6) 56% (5) 0% (0) 
Piloerection 0% (0) 0% (0) 17% (2) 33% (6) 39% (5) 0% (0) 
Touch response decreased 0% (0) 17% (2) 72% (6) 50% (4) 83% (6) 0% (0) 
Body tonus decreased 0% (0) 50% (5) 50% (5) 22% (3) 33% (5) 0% (0) 
Traction response decreased 0% (0) 6% (1) 28% (3) 6% (1) 11% (1) 6% (1) 
Sedation 0% (0) 11% (1) 56% (6) 56% (6) 56% (6) 0% (0) 
Pinna reflex decreased 0% (0) 11% (1) 11% (1) 33% (3) 11% (1) 11% (1) 
Ptosis 0% (0) 17% (2) 56% (6) 50% (5) 44% (6) 0% (0) 
Abnormal urination (increased) 0% (0) 0% (0) 0% (0) 0% (0) 22% (4) 0% (0) 
Vehicle for 
clonidine 




Spontaneous activity decreased 50% (6) 61% (6) 83% (6) 83% (6) 67% (6) 0% (0) 
Flat body posture 22% (1) 33% (3) 33% (3) 11% (1) 0% (0) 0% (0) 
Piloerection 17% (2) 17% (3) 28% (3) 56% (5) 22% (3) 0% (0) 
Touch response decreased 0% (0) 39% (4) 6% (1) 11% (1) 22% (3) 0% (0) 
Traction response decreased 44% (3) 22% (2) 28% (3) 50% (4) 44% (3) 6% (1) 
Body tonus decreased 17% (2) 17% (3) 6% (1) 6% (1) 11% (1) 0% (0) 
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Ptosis 0% (0) 22% (1) 28% (3) 33% (3) 44% (4) 0% (0) 
Absence of blink reflex 67% (6) 56% (5) 56% (5) 11% (1) 33% (3) 0% (0) 
Abnormal respiration 67% (6) 67% (6) 56% (5) 67% (6) 61% (6) 0% (0) 
Vehicle for 
amphetamine 




Spontaneous activity increased 50% (6) 83% (6) 67% (6) 67% (6) 67% (6) 0% (0) 
Rearing increased 17% (3) 33% (3) 67% (6) 67% (6) 67% (6) 0% (0) 
Sniffing increased 17% (3) 17% (3) 17% (3) 17% (3) 50% (6) 0% (0) 
Piloerection 33% (3) 50% (6) 33% (3) 50% (6) 22% (4) 0% (0) 
Touch response increased 0% (0) 50% (6) 72% (6) 83% (6) 44% (4) 0% (0) 
Traction response decreased 22% (3) 17% (1) 0% (0) 17% (1) 6% (1) 6% (1) 
Pinna reflex decreased 11% (1) 0% (0) 44% (4) 22% (2) 33% (3) 0% (0) 
 
Table 3: The neurobehavioural effects from the modified Irwin test for chlorpromazine, clonidine and amphetamine 
exposure in rats.      
The table shows the percentage of maximum possible score (%MPS) and the number of animals with the observation in brackets 
for symptoms where 1 or more animals after oral administration of the respective compounds (n=6 per group per compound) exhibit 
the symptom.  No effect is scored as 0.  Data in bold are considered to be a significant effect in the modified Irwin test observation, 
whereby they have been observed in animals in the test agent groups with ≥n=3 of the same symptom observed in their respective 
vehicle groups.  The observed symptoms for each rat were scored from 1 to 3 based on severity of the symptom.  The observed 
symptoms for each treatment group at each observed time point were then presented as the dose group mean of the %MPS 
















Mean difference (95%CI) 
Modified Irwin Test data Rectal probe 
15 min 0% (0) 0% (0) 0% (0) 17% (3) 
 
30 min 0% (0) 0% (0) 0% (0) 56% (6) 
 
1h 0% (0) 0% (0) 17% (2) 78% (6) -1.3°C (-1.04 to -1.53) 
2h 0% (0) 0% (0) 33% (6) 100% (6) 
 
4h  0% (0) 0% (0) 39% (5) 56% (5) -1.0°C (-0.43 to -1.54) 
24h 0% (0) 0% (0) 0% (0) 0% (0) +0.7°C (0.23 to 1.17) 
Home Cage observation from ActualHCA™  RFID transponder 
15 min 11% (2) 0% (0) 0% (0) 0% (0) 
 
30 min 28% (5) 6% (1) 0% (0) 56% (5) -0.7°C (-0.15 to -1.20) 
1h  22% (4) 0% (0) 0% (0) 67% (6) -0.6°C (-0.001 to -1.23) 
2h  0% (0) 6% (1) 0% (0) 67% (6) -0.6°C (-0.17 to -1.38) 
4h  0% (0) 0% (0) 0% (0) 56% (5) -1.1°C (-0.34 to -1.92) 
24h  0% (0) 0% (0) 0% (0) 0% (0) +0.3°C (-0.07 to 0.70) 
 
Table 4: Comparison of the parameters observed in the home cage using both 
the modified Irwin test and from ActualHCA™, following the administration of 
chlorpromazine or vehicle in rats.   
The observed behavioural effects for each rat were scored from 1 to 3 based on 
severity of the symptom (n=6/group).  No effect is scored as 0.  The observed 
behavioural effects for each method at each observed timepoint are presented as 
the dose group mean of the percentage of maximum possible severity score 
[score/max score*100], and the number of rats exhibited the behavioural effect in 
brackets.  Behavioural effects are considered significant and highlighted in bold, in 
the modified Irwin test or ActualHCA™, whereby they have been observed in the 
animals in the test agent groups with ≥n=3 with the same symptoms observed in 
their respective vehicle groups.  None of the symptoms listed were observed with the 
vehicle groups.  The effect of the drug on temperature is presented as the mean 
difference between vehicle and chlorpromazine groups, with the 95% confidence 
interval (CI) in brackets.  Effects on temperature were analysed using a student’s t-
test with multiple testing adjustment to control the false discovery rate to 5% within 
each datasets for a variable and drug using the Benjamini and Hochberg 
methodology.  Blank cells indicate the assessment was not performed at that 






Abnormal gait Spontaneous 
activity decreased 
Temperature: 
Mean difference (95%CI) 
Modified Irwin Test data Rectal probe 
15 min 0% (0) 50% (6) 
 
30 min 0% (0) 61% (6) 
 
1h  0% (0) 83% (6) -2.1oC (-1.44 to -2.82) 
2h  0% (0) 83% (6)  
4h  0% (0) 67% (6)  
24h  0% (0) 0% (0)  
Home Cage observation from ActualHCA™ RFID transponder 
15 min 11% (2) 44% (6) 
 
30 min 0% (0) 67% (6) -0.7oC (-0.08 to -1.30) 
1h  0% (0) 50% (6) -0.9oC (-0.21 to -1.68) 
2h  0% (0) 0% (0) -1.0oC (-0.53 to -1.49) 
4h  0% (0) 50% (6) -0.5oC (-1.07 to 0.11) 
24h  0% (0) 0% (0) -0.1oC (-0.73 to 0.60) 
 
Table 5: Comparison of the parameters observed in the home cage using both 
the modified Irwin test and from ActualHCA™, following the administration of 
clonidine or vehicle in rats.   
The observed behavioural effects for each rat were scored from 1 to 3 based on 
severity of the symptom (n=6/group).  No effect is scored as 0.  The observed 
behavioural effects for each method at each observed timepoint are presented as 
the dose group mean of the percentage of maximum possible severity score 
[score/max score*100], and the number of rats exhibited the behavioural effect in 
brackets.  Behavioural effects are considered significant and highlighted in bold, in 
the modified Irwin test or ActualHCA™, whereby they have been observed in the 
animals in the test agent groups with ≥n=3 with the same symptoms observed in 
their respective vehicle groups.  None of the symptoms listed were observed with the 
vehicle groups.  The effect on temperature is presented as the mean difference 
between vehicle and chlorpromazine groups, with the 95% confidence interval (CI) in 
brackets.  Effects on temperature were analysed using a student’s t-test with multiple 
testing adjustment to control the false discovery rate to 5% within each datasets for a 
variable and drug using the Benjamini and Hochberg methodology.  Blank cells 
indicate the assessment was not performed at that timepoint, therefore data are not 
















Mean difference (95%CI) 
Modified Irwin Test data Rectal probe 
15 min 33% (3) 17% (3) 17% (3) 50% (6) 
 
30 min 50% (6) 33% (3) 17% (3) 83% (6) 
 
1h  33% (3) 67% (6) 17% (3) 67% (6) +0.7oC (0.23 to 1.17) 
2h  50% (6) 67% (6) 17% (3) 67% (6)  
4h  22% (4) 67% (6) 50% (6) 67% (6) +1.0oC (0.59 to 1.34) 
24h  0% (0) 0% (0) 0% (0) 0% (0) -0.3oC (-0.67 to 0.19) 
Home Cage observation from RBB video footage  RFID transponder 
15 min 0% (0) 33% (6) 67% (6) 67% (6) 
 
30 min 17% (3) 33% (6) 67% (6) 67% (6) +0.9oC (0.26 to 1.59) 
1h  6% (1) 22% (4) 67% (6) 67% (6) +1.4oC (0.74 to 2.10) 
2h  0% (0) 17% (3) 28% (5) 67% (6) +1.4oC (0.39 to 2.40) 
4h  0% (0) 11% (2) 28% (5) 61% (6) +0.7oC (-0.36 to 1.74) 
24h  0% (0) 0% (0) 0% (0) 0% (0) +0.1oC (-0.59 to 0.81) 
 
Table 6: Comparison of the parameters observed in the home cage using both 
the modified Irwin test and from ActualHCA™, following the administration of 
amphetamine or vehicle in rats.   
The observed behavioural effects for each rat were scored from 1 to 3 based on 
severity of the symptom (n=6/group).  No effect is scored as 0.  The observed 
behavioural effects for each method at each observed timepoint are presented as 
the dose group mean of the percentage of maximum possible severity score 
[score/max score*100], and the number of rats exhibited the behavioural effect in 
brackets.  Behavioural effects are considered significant and highlighted in bold, in 
the modified Irwin test or ActualHCA™, whereby they have been observed in the 
animals in the test agent groups with ≥n=3 with the same symptoms observed in 
their respective vehicle groups.  None of the symptoms listed were observed with the 
vehicle groups.  The effect of the drug on temperature is presented as the mean 
difference between vehicle and chlorpromazine groups, with the 95% confidence 
interval (CI) in brackets.  Effects on temperature were analysed using a student’s t-
test with multiple testing adjustment to control the false discovery rate to 5% within 
each datasets for a variable and drug using the Benjamini and Hochberg 
methodology.  Blank cells indicate the assessment was not performed at that 









Figure 1.  The effects of chlorpromazine compared with vehicle, on activity in 
rats. 
Male Han Wistar rats (n=6/group) were dosed orally with chlorpromazine at 30 
mg/kg, or vehicle (10 mL/kg).  Ambulatory activity, expressed as the number of 
transitions (left panel), and in time spent rearing, expressed in seconds (right panel) 
were recorded for 24h from immediately post-dose using ActualHCA™.  A) + B); 
dosing occurred during the light phase at approximately 09:00h.  C) + D); dosing 
occurred during the dark phase at approximately 20:00h.  E) + F); dosing occurred 
during the light phase at approximately 09:00h, with a scheduled cage-change at 
11:00h.  At each time point the treatment data were compared to vehicle using a 
student’s t-test with multiple testing adjustment to control the false discovery rate to 
5% within each datasets for a variable and drug using the Benjamini and Hochberg 
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Figure 2.  The effects of clonidine compared with vehicle, on activity in rats. 
Male Han Wistar rats (n=6/group) were dosed orally with clonidine at 0.3 mg/kg, or 
vehicle (10 mL/kg).  Ambulatory activity, expressed as the number of transitions (left 
panel), and in time spent rearing, expressed in seconds (right panel) were recorded 
for 24h from immediately post-dose using ActualHCA™.  A) + B); dosing occurred 
during the light phase at approximately 09:00h.  C) + D); dosing occurred during the 
dark phase at approximately 20:00h.  E) + F); dosing occurred during the light phase 
at approximately 09:00h, with a scheduled cage-change at 10:00h.  At each time 
point the treatment data were compared to vehicle using a student’s t-test with 
multiple testing adjusted to control the false discovery rate to 5% within each 
datasets for a variable and drug using the Benjamini and Hochberg methodology. 









Figure 3.  The effects of amphetamine compared with vehicle, on activity in 
rats. 
Male Han Wistar rats (n=6/group) were dosed orally with amphetamine at 10 mg/kg, 
or vehicle (10 mL/kg).  Ambulatory activity, expressed as the number of transitions 
(left panel), and in time spent rearing, expressed in seconds (right panel) were 
recorded for 24h from immediately post-dose using ActualHCA™.  A) + B); dosing 
occurred during the light phase at approximately 09:00h.  C) + D); dosing occurred 
during the dark phase at approximately 20:00h.  E) + F); dosing occurred during the 
light phase at approximately 09:00h, with a scheduled cage-change at 11:00h.  At 
each timepoint the treatment data were compared to vehicle using a student’s t-test 
with multiple testing adjustment to control the false discovery rate to 5% within each 
datasets for a variable and drug using the Benjamini and Hochberg methodology. 










Figure 4.  The effects of chlorpromazine, clonidine and amphetamine 
compared with vehicle, on temperature in rats. 
Male Han Wistar rats (n=6/group) were dosed orally with chlorpromazine at 30 mg/kg 
(A, B, C), clonidine at 0.3 mg/kg (D, E, F), amphetamine at 10 mg/kg (G, H, I), or 
vehicle (10 mL/kg) and the subcutaneous temperature monitored.  The left panel (A, 
D, G): dosing during the light phase at approximately 09:00h.  The middle panel (B, 
E, H): dosing during the dark phase at approximately 20:00h.  The right panel (C, F, 
I): dosing during the light phase at approximately 09:00h, with a scheduled cage-
change at 10:00h for clonidine, and 11:00h for chlorpromazine and amphetamine.  At 
each timepoint the treatment data were compared to vehicle using a student’s t-test 
with multiple testing adjustment to control the false discovery rate to 5% within each 
datasets for a variable and drug using the Benjamini and Hochberg methodology. 
*P<0.05; **P<0.01; ***P<0.001.  
A) B) C) 
D) E) F) 
G) H) I) 
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Chlorpromazine Timepoints (post-dose) 
16h 17h 18h 
Spontaneous 
activity decreased 
56% (5) 28% (3) 6% (1) 
Spontaneous 
activity increased 
0% (0) 0% (0) 0% (0) 
Clonidine Timepoints (post-dose) 
12h 14.5h 21h 
Spontaneous 
activity decreased 
0% (0) 0% (0) 0% (0) 
Spontaneous 
activity increased 
0% (0) 17% (3) 50% (6) 
Amphetamine Timepoints (post-dose) 
8h 12h 14h 
Spontaneous 
activity decreased 
11% (2) 17% (3) 22% (3) 
Spontaneous 
activity increased 
0% (0) 0% (0) 0% (0) 
 
Table 7.  Results from the additional modified Irwin test conducted from 
ActualHCA™ video at 3 delayed time points for chlorpromazine, clonidine and 
amphetamine in rats.   
The observed behavioural effects for each rat were scored from 1 to 3 based on 
severity of the symptom (n=6/group).  No effect is scored as 0.  The observed 
behavioural effects for each method at each observed timepoint are presented as 
the dose group mean of the percentage of maximum possible severity score 
[score/max score*100], and the number of rats exhibited the behavioural effect in 
brackets.  Behavioural effects are considered significant and highlighted in bold, 
whereby they have been observed in the animals in the test agent groups with ≥n=3 
with the same symptoms observed in their respective vehicle groups.  None of the 
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